EYEric M. Yoshida

Eric M. Yoshida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric M. Yoshida has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review

    by Kai Zhu, Eric Wu, Benson Tam, Eric M. Yoshida, Peter Kwan

    We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.

  • Open Access

    Anti-SLA and AMA-positive celiac disease: A report of two cases and evaluation of autoimmune liver serology

    by Nurhan Demir, Cumali Efe, Seyhmus Olmez, Arzu Onur, Eric M. Yoshida

    Background and Aim: Antibodies to soluble liver antigen (anti-SLA) and anti-mitochondrial autoantibodies (AMA) are two specific serological markers of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). They are rarely detected in the sera of patients with non-liver autoimmune disorders. Materials and Methods: The biochemical, serological, and histological findings of two celiac disease (CD) patients who were seropositive for anti-SLA and/or AMA were evaluated. Results: The data of two female patients who were 28 and 34 years old at the time of CD diagnosis were analyzed. The first patient presented with elevated liver function tests (LFTs) and immunoglobulin (Ig) G values. She was seropositive for both anti-SLA and AMA. A liver biopsy suggested features of AIH but no bile duct injury was noted. In addition to a gluten-free diet (GFD), immunosuppressive therapy was administered to normalize the LFTs. The second patient presented with elevated LFTs, a high IgG level, and a positive anti-SLA finding. A GFD was initiated, which resulted in an excellent clinical and biochemical response. Seropositivity for AMA in the first patient and anti-SLA in the second patient remained unchanged during follow-up but neither patient developed primary biliary cholangitis or AIH. Conclusion: Despite the high specificity of anti-SLA and AMA, these autoantibodies can be detected in CD without having any clinical relevance.